{"symbol": "VCYT", "companyName": "Veracyte Inc", "exchange": "NASDAQ", "industry": "Medical Laboratories ", "website": "www.veracyte.com", "description": "Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.", "CEO": "Bonnie Anderson", "securityName": "Veracyte Inc", "issueType": "cs", "sector": "Health Care and Social Assistance", "primarySicCode": 8071, "employees": null, "tags": ["Health Technology", "Biotechnology", "Health Care and Social Assistance", "Medical Laboratories "], "address": "6000 Shoreline Ct Ste 300", "address2": null, "state": "California", "city": "South San Francisco", "zip": "94080-7606", "country": "US", "phone": "16502436300"}